Find in Library

The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the eect of<br />pneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimate<br />the direct costs of hospitalized IPD cases. A prospective study was made in children aged <5 years<br />diagnosed with IPD in two high-tech hospitals in Catalonia (Spain) between 2007–2009 (PCV7 period)<br />and 2012–2015 (PCV13 period). Costs were calculated according to 2014 Catalan Health Service rates<br />using diagnostic-related groups. In total, 319 and 154 cases were collected, respectively. Pneumonia<br />had the highest cost (65.7% and 62.0%, respectively), followed by meningitis (25.8% and 26.1%,<br />respectively). During 2007–2015, the costs associated with PCV7 serotypes (Pearson coecient (Pc) =<br />?0.79; p = 0.036) and additional PCV13 serotypes (Pc = ?0.75; p = 0.05) decreased, but those of other<br />serotypes did not (Pc = 0.23 p = 0.62). The total mean cost of IPD increased in the PCV13 period by<br />31.4% (¿3016.1 vs. ¿3963.9), mainly due to ICU stay (77.4%; ¿1051.4 vs. ¿1865.6). During the PCV13<br />period, direct IPD costs decreased due to a reduction in the number of cases, but cases were more severe and had a higher mean cost. During 2015, IPD costs increased due to an increase in the costs<br />associated with non-PCV13 serotypes and serotype 3 and this requires further investigation.